Dental Buying Power LLC
$6.2M 0 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
PharmaEssentia USA Corporation
PharmaEssentia USA Corporation reported $6,256,064.12 across General Payments, Research, and Ownership to 4,725 physicians and teaching hospitals across 5,160 transactions.
- $6.3M Top quartile payer
- All-tracks total
- 5,160 Top quartile volume
- Transactions
- 4,725 Top quartile reach
- Recipients
- −$87.9K
- General Payments vs PY2023
PharmaEssentia USA Corporation reported $6,256,064.12 across all CMS Open Payments tracks (General + Research + Ownership) to 4,725 physicians and teaching hospitals in Program Year 2024 - ranking #233 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $714,473.56, averaging $1.3K per recipient.
How PharmaEssentia USA Corporation's $6.3M all-tracks total breaks down
PharmaEssentia USA Corporation's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
D
60/100
Total payments
C
68/100
Transaction volume
F
48/100
Physician reach
F
46/100
Payment type diversity
C
77/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer pharmaessentia-usa-corporation PharmaEssentia USA Corporation
$6.3M · #233/1,925 · 0.0% industry · PY2024
- TOT $6.3M
- RANK #233
- SHARE 0.0%
- TXN 5,160
- RCP 4,725
- CAT 6
- GEN $714.5K
- ΔGEN −$87.9K
- TOP1 25.0%
- PY 2024
Volume peers
Nearest volume peer: Dental Buying Power LLC ($6.2M)
PharmaEssentia USA Corporation sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
PharmaEssentia USA Corporation's CMS-reported General Payments decreased by $87.9K (−11.0%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: PHARMAESSENTIA USA CORPORATIONPY2023: PHARMAESSENTIA USA CORPORATIONPY2024: PharmaEssentia USA Corporation. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $802,381.40
- PY2024
- $714,473.56
What the Data Shows for PharmaEssentia USA Corporation
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For PharmaEssentia USA Corporation, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 6-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Space Rental or Facility Fees" at $290.4K, accounting for 40.6% of this company's General Payments and 37 transactions.
General Payment Breakdown by Type
PharmaEssentia USA Corporation made 6 types of general payments. "Space Rental or Facility Fees" is the largest category at $290.4K, 40.6% of General Payments.
PharmaEssentia USA Corporation reports 6 general-payment categories - the top three are Space Rental or Facility Fees (40.6%), Consulting Fee (25.8%), and Food and Beverage (16.6%). The remaining 3 categories make up 16.9% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How PharmaEssentia USA Corporation divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Space Rental or Facility Fees | $290.4K | 37 | 40.6% |
| Consulting Fee | $184.6K | 56 | 25.8% |
| Food and Beverage | $118.5K | 4,554 | 16.6% |
| Compensation for Services Other Than Consulting | $77.2K | 37 | 10.8% |
| Honoraria | $30.6K | 15 | 4.3% |
| Travel and Lodging | $13.1K | 26 | 1.8% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $275,179.33 (38.5%) of $714,473.56 in this company's General Payments records across 2,794 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for PharmaEssentia USA Corporation
The five named recipients with the highest reported General Payments from this company
- 1
U Of Utah Neuropsychiatric Institute
$178,750.00 across 3 reported transactions
- 2
James Mccloskey
$30,789.49 across 18 reported transactions
- 3
Alan Rodney
$23,429.49 across 23 reported transactions
- 4
Brandi Reeves
$22,093.09 across 7 reported transactions
- 5
Mojtaba Akhtari
$20,117.26 across 9 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
PharmaEssentia USA Corporation ranks #233 of 1,925 by total payments (top 12% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,158 of 1,838 by HHI (bottom 37% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Novo Nordisk Health Care AG : $442.0K total payments, HHI 746
- McKesson Medical-Surgical Minnesota Supply, Inc : $837.57 total payments, HHI 746
- CTL Medical Corporation : $565.3K total payments, HHI 745
- Uswm, LLC : $57.8K total payments, HHI 743
- Tokuyama Dental America Inc. : $79.2K total payments, HHI 733
- Samsung Bioepis Co., Ltd. : $85.2K total payments, HHI 728
- PharmaEssentia USA Corporation (this company) : $714.5K total payments, HHI 727
- Exactech, Inc. : $8.1M total payments, HHI 722
- Guerbet LLC : $589.2K total payments, HHI 722
- Valley Contax, Inc. : $90.4K total payments, HHI 721
- Intera Oncology, Inc : $90.9K total payments, HHI 720
- EMD Serono Research & Development Institute, Inc. : $320.3K total payments, HHI 719
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as PharmaEssentia USA Corporation's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about PharmaEssentia USA Corporation.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with PharmaEssentia USA Corporation.
Showing 6 of 1,924 companies with CMS-reported payment data.
CooperVision Inc.
$6.2M 29,989 recipients
Compare payment profiles
Davol Inc.
$6.2M 12,178 recipients
Compare payment profiles
Baxter Healthcare
$6.4M 26,086 recipients
Compare payment profiles
Sobi, Inc
$6.1M 16,390 recipients
Compare payment profiles
Agios Pharmaceuticals, Inc.
$6.1M 3,134 recipients
Compare payment profiles
Put this to use
PharmaEssentia USA Corporation ranks #233 of 1,925 by all-tracks total payments, led by "Space Rental or Facility Fees".
- See where PharmaEssentia USA Corporation sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Space Rental or Facility Fees" spend across every manufacturer, not just PharmaEssentia USA Corporation. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.